Showing results (221-230 of 295) with videos related to
Sort By:
Pageof 30
Breast Cancer Research and Treatment|August 6, 2017
Early onset breast cancer: differences in risk factors, tumor phenotype, and genotype between North African and South European womenCarole Corsini, Sarra Henouda, Dalel Ben Nejima, et al.Cancer|June 18, 2016
Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609)Florence Lerebours, Sofia Rivera, Marie-Ange Mouret-Reynier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2008
Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancerMarc Ychou, David Azria, Cathy Menkarios, et al.International Journal of Radiation Oncology, Biology, Physics|October 13, 2007
Phyllodes tumor of the breastYazid Belkacémi, Guilhem Bousquet, Hugo Marsiglia, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2010
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II studyJean-Luc Van Laethem, Pascal Hammel, Françoise Mornex, et al.Critical Reviews in Oncology/Hematology|May 26, 2020
The 2018 assisi think tank meeting on breast cancer: International expert panel white paperMeritxell Arenas, Ugur Selek, Orit Kaidar-Person, et al.Oncotarget|April 29, 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trialEric Assenat, David Azria, Caroline Mollevi, et al.International Journal of Radiation Oncology, Biology, Physics|May 17, 2011
Anal canal cancer: management of inguinal nodes and benefit of prophylactic inguinal irradiation (CORS-03 Study)Cécile Ortholan, Michel Resbeut, Jean-Michel Hannoun-Levi, et al.Clinical and Translational Radiation Oncology|December 19, 2023
Prospective results for 5-year survival and toxicity of moderately hypofractionated radiotherapy with simultaneous integrated boost (SIB) in (very) high-risk prostate cancerIngrid Masson, Laurène Larriviere, Marc-André Mahé, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 7, 2019
Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failureMaïlys de Meric de Bellefon, Claire Lemanski, Florence Castan, et al.Pageof 30